Ovid Therapeutics Q3 2026 Results: Net Loss of $20.8M, Loss Widens
Ovid Therapeutics reported a net loss of $52.8 million for the nine months ended September 30, 2026, compared to a $27.1 million loss in the prior year period. The increase in loss was primarily driven by a significant rise in research and development expenses, which grew from $19.0 million to $36.8 million year-over-year.
- Key figure
- Net loss $20.8M